{
  "id": "602598101cb411341a0000ae",
  "type": "factoid",
  "question": "What does tsDMARD stand for?",
  "ideal_answer": "tsDMARDs are targeted synthetic disease-modifying antirheumatic drugs.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32550671",
    "http://www.ncbi.nlm.nih.gov/pubmed/31504972",
    "http://www.ncbi.nlm.nih.gov/pubmed/32179964",
    "http://www.ncbi.nlm.nih.gov/pubmed/31787605",
    "http://www.ncbi.nlm.nih.gov/pubmed/31426398",
    "http://www.ncbi.nlm.nih.gov/pubmed/30941350",
    "http://www.ncbi.nlm.nih.gov/pubmed/30128641",
    "http://www.ncbi.nlm.nih.gov/pubmed/28831712",
    "http://www.ncbi.nlm.nih.gov/pubmed/32896492",
    "http://www.ncbi.nlm.nih.gov/pubmed/31682274",
    "http://www.ncbi.nlm.nih.gov/pubmed/27118331"
  ],
  "snippets": [
    {
      "text": "Whether this potential risk is specific to abatacept or extends to all biologics and targeted synthetic DMARDs (tsDMARDs) is unclear. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31504972",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To provide real-world evidence about the reasons why Australian rheumatologists cease biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) when treating patients with rheumatoid arthritis (RA), and to assess (1) the primary failure rate for first-line treatment, and (2) the persistence on second-line treatments in patients who stopped first-line tumor necrosis factor inhibitors (TNFi).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31787605",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The treatment of rheumatoid arthritis (RA) has been transformed with the introduction of biologic disease modifying anti-rheumatic drugs (bDMARD) and more recently, targeted synthetic DMARD (tsDMARD) therapies in the form of janus-kinase inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30941350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite recommendations suggesting that biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with methotrexate in the treatment of rheumatoid arthritis (RA), up to one-third of patients with RA are treated with monotherapy. Th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30128641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Many biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are currently available as treatment options for rheumatoid arthritis (RA), but a subset of RA patients shows inadequate responses to any of these DMARDs. This",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32896492",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A Jak inhibitor tofacitinib, the first drug of targeted synthetic DMARD (tsDMARD), a novel category of DMARD, shows similar efficacy profile, but different safety concerns, compared to bDMARDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27118331",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical trials of biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have included fatigue as a secondary endpoint.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31682274",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, targeted synthetic DMARDs (tsDMARDs) inhibiting Janus kinase (JAK) and biosimilars also are approved for RA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28831712",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment wise, great progress has been achieved over the last decades with the discovery and introduction in therapeutics of new molecules, such as the biological (b) disease-modifying anti-rheumatic drugs (DMARDs), and the targeted synthetic (ts) DMARDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31426398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The progress in the understanding of the pathophysiology of rheumatic diseases provided a rational basis for the development of biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) which have completely revolutionized the treatment of inflammatory conditions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32550671",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These new drugs consist of biologicals (biological disease-modifying antirheumatic drugs, bDMARDs) as well as targeted synthetic DMARDs (tsDMARD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32179964",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "targeted synthetic disease-modifying antirheumatic drugs"
}